Anagenics (ASX:AN1) said it expects to complete the relisting of its securities on the Australian Securities Exchange by the end of February, following the submission of additional required information to the exchange, according to a Jan. 10 filing with the Australian bourse.
The additional information required includes its quarterly activities report, an audit-reviewed financial statement, and confirmation of sufficient operations and financial standing following its recent restructure, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.